Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

2 Top Growth Stocks Set Annual Highs on Tuesday -- Are They Buys?

By Beth McKenna - Nov 13, 2019 at 9:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of this AI leader and diabetes specialist seem to have long runways for growth.

On Tuesday, Nov. 12, the major stock market indexes were flat to up very slightly, though more stocks declined than rose.

As is nearly always the case, some stocks continued to move higher and set new annual highs during the trading day. Of's universe of 3,506 stocks, small-cap and larger, 201 -- less than 6% -- fell into this rather exclusive club. 

Two stocks among this group that look particularly interesting are graphics chip specialist NVIDIA ( NVDA 1.08% ) and diabetes-focused medical device maker Insulet ( PODD 1.03% ). Insulet's new annual high is also a new all-time high.

Letters "AI" comprised of electronic circuit board and office buildings in background.

Image source: Getty Images.



Market Cap

Forward P/E

Wall Street's Projected Average Annual EPS Growth Over Next 5 Years

YTD 2019 Stock Return

5-Year Stock Return

NVIDIA $127.7 billion 29.4 12.5% 57.5% 1,010%
Insulet $11 billion 236 172% 124% 282%
S&P 500 -- -- -- 25.4% 68.1%

Data sources: Yahoo! Finance and P/E = price to earnings ratio. EPS = earnings per share. YTD = year to date. Data as of Nov. 12, 2019.


NVIDIA started life as a maker of graphics processing units (GPUs) for computer gaming. That's a huge and growing market in which the Silicon Valley-based company is the market leader. But the main impetus for the stock's taking off a few years ago was NVIDIA's success in its newer businesses, namely its artificial intelligence-driven data center and driverless vehicle-powered auto platforms.

Along with these massive growth trends, it's also involved in just about every other major emerging technology trend, including virtual reality, drones, smart cities, and more. Moreover, the company is led by its founder, Jensen Huang, who has proven to be very shrewd.  

NVIDIA's results have begun recovering nicely from the hit it took starting in the fourth quarter of last year. That's when the gaming business was stuck with a glut of graphics cards due to the cryptocurrency bust, which was soon followed by a slowdown in the data center business. Investors will soon learn how the rebound is progressing, as NVIDIA is scheduled to report its third-quarter results for fiscal 2020 on Thursday, Nov. 14, after the market closes. (Here's what to watch in the company's Q3 report.) 


Insulet, based in Massachusetts, is the leader in tubeless insulin pump technology. Its wearable Omnipod is marketed to people with type 1 and insulin-requiring type 2 diabetes. Folks with these conditions have been embracing the pump, finding it more convenient than either multiple daily injections or pumps with tubes. The Omnipod should win over even more converts when Insulet launches its Horizon system, an automated insulin delivery system that uses a DexCom continuous glucose monitor. This rollout is planned for late 2020.

The number of people diagnosed with type 2 diabetes in the United States and other developed countries continues to grow at a solid pace, driven by the aging and "heavying" of the population.

In the third quarter, Insulet's revenue jumped 27% year over year and adjusted earnings per share tripled. Thanks to the company's better-than-expected results and strong start to the fourth quarter, management increased its full-year revenue guidance and now expects revenue growth of 28% to 29% year over year. 

Is either of these stocks a buy?

I'd unhesitatingly call NVIDIA a buy for most long-term investors, excepting those who are quite conservative and/or income oriented, as the company's dividend isn't worth mentioning. (The yield is just 0.3%). 

Insulet is worth considering if you're a risk-tolerant investor comfortable with stocks with sky-high valuations -- meaning that they could be quite volatile. Ideally, you should also be willing to keep up with the broader diabetes market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NVIDIA Corporation Stock Quote
NVIDIA Corporation
$330.31 (1.08%) $3.54
Insulet Corporation Stock Quote
Insulet Corporation
$291.40 (1.03%) $2.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.